Ginger Denison - Liquidia Technologies CoFounder
| LQDA Stock | USD 12.79 0.19 1.46% |
Insider
Ginger Denison is CoFounder of Liquidia Technologies
| Address | 419 Davis Drive, Morrisville, NC, United States, 27560 |
| Phone | 919 328 4400 |
| Web | https://www.liquidia.com |
Liquidia Technologies Management Efficiency
The company has return on total asset (ROA) of (0.3706) % which means that it has lost $0.3706 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1401) %, meaning that it created substantial loss on money invested by shareholders. Liquidia Technologies' management efficiency ratios could be used to measure how well Liquidia Technologies manages its routine affairs as well as how well it operates its assets and liabilities. As of May 4, 2024, Return On Tangible Assets is expected to decline to -0.73. The current year's Return On Capital Employed is expected to grow to -0.68. At present, Liquidia Technologies' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 2.3 M, whereas Total Assets are forecasted to decline to about 80.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christine Chiou | Incyte | N/A | |
| Mary Jenkins | Sarepta Therapeutics | N/A | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Michael Esq | TG Therapeutics | 58 | |
| Jeff York | Seres Therapeutics | N/A | |
| James Kihara | ACADIA Pharmaceuticals | 43 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
| William Ciambrone | Sarepta Therapeutics | 60 | |
| MBA MBA | Incyte | 64 | |
| David MBA | Seres Therapeutics | 63 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Marianne Mancini | Viking Therapeutics | 59 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Maria JD | Incyte | 58 | |
| Brendan Teehan | ACADIA Pharmaceuticals | 55 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| CPA CPA | TG Therapeutics | 42 | |
| MSPH MD | ACADIA Pharmaceuticals | 67 | |
| John Schembri | Akero Therapeutics | 62 | |
Management Performance
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.37 |
Liquidia Technologies Leadership Team
Elected by the shareholders, the Liquidia Technologies' board of directors comprises two types of representatives: Liquidia Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Liquidia. The board's role is to monitor Liquidia Technologies' management team and ensure that shareholders' interests are well served. Liquidia Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Liquidia Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Almond, Director Communications | ||
| Neal Fowler, CEO and Director | ||
| Kevin Gordon, President CFO | ||
| Robert Lippe, Chief Operations Officer | ||
| Russell Schundler, General Secretary | ||
| Seth Rudnick, Chairman of the Board | ||
| Ginger Denison, CoFounder | ||
| Richard Katz, CFO | ||
| Timothy Albury, Interim CFO | ||
| Roger Jeffs, CEO Director | ||
| Benjamin Maynor, Senior Vice President - Research & Development | ||
| William Kenan, CoFounder | ||
| Edward Mathers, Director | ||
| Jason Adair, Chief Officer | ||
| Celia ReyesHoke, VP Culture | ||
| Tushar MD, Senior Development | ||
| Sarah SPHR, Vice Culture | ||
| Scott Moomaw, Chief Officer | ||
| Michael Kaseta, Chief Officer |
Liquidia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Liquidia Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (5.83) % | ||||
| Current Valuation | 938.25 M | ||||
| Shares Outstanding | 76.38 M | ||||
| Shares Owned By Insiders | 12.34 % | ||||
| Shares Owned By Institutions | 51.28 % | ||||
| Number Of Shares Shorted | 8.07 M | ||||
| Price To Earning | (2.61) X | ||||
| Price To Book | 22.43 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Liquidia Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Liquidia Stock refer to our How to Trade Liquidia Stock guide.Note that the Liquidia Technologies information on this page should be used as a complementary analysis to other Liquidia Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Liquidia Stock analysis
When running Liquidia Technologies' price analysis, check to measure Liquidia Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Liquidia Technologies is operating at the current time. Most of Liquidia Technologies' value examination focuses on studying past and present price action to predict the probability of Liquidia Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Liquidia Technologies' price. Additionally, you may evaluate how the addition of Liquidia Technologies to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Liquidia Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Liquidia Technologies. If investors know Liquidia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Liquidia Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.21) | Revenue Per Share 0.269 | Quarterly Revenue Growth (0.15) | Return On Assets (0.37) | Return On Equity (1.14) |
The market value of Liquidia Technologies is measured differently than its book value, which is the value of Liquidia that is recorded on the company's balance sheet. Investors also form their own opinion of Liquidia Technologies' value that differs from its market value or its book value, called intrinsic value, which is Liquidia Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Liquidia Technologies' market value can be influenced by many factors that don't directly affect Liquidia Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Liquidia Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Liquidia Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Liquidia Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.